A randomized controlled trial into the efficacy of neurofeedback for treatment of major depressive disorder

Phase 3

Recruiting

• Conditions: depression; major depressive disorder; 10027946

• Registration Number: NL-OMON41680
• Lead Sponsor: Medisch Universitair Ziekenhuis Maastricht

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 29 April 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 50

Inclusion Criteria

• Primary axis-1 disorder of Major Depressive Disorder fulfilling DSM-IV-TR criteria.
• Written informed consent.

Exclusion Criteria

• History of brain trauma (commotio or contusio cerebra) or CVA
• Current use of antipsychotics, moodstabilizers or benzodiazepines. Current use of antidepressants is permitted if this medication is not changed within a period of 6 weeks prior to participation in the study. Additionally, no changes in antidepressant medication are allowed during active participation in the study.
• Chronic depression (> two years duration).
• Dysthymia as a primary axis-1 diagnosis
• Bipolar disorder or schizophrenia as a primary axis-1 diagnosis
• Severe suicidality (HDRS item # 3 with a score >2) or severe depression symptomatology (HDRS score > 25).
• Pregnancy.
• Age < 18 years.
• Daily alcoholintake of >7 units.

Study & Design

• Study Type: Interventional
• Study Design: Not specified